Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 15 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Elisaf, Moses  [Clear All Filters]
2018
Kotsis, V., Jordan J., Micic D., Finer N., Leitner D. R., Toplak H., et al. (2018).  Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension. J Hypertens. 36(7), 1427-1440.
Kotsis, V., Tsioufis K., Antza C., Seravalle G., Coca A., Sierra C., et al. (2018).  Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, ea. J Hypertens. 36(7), 1441-1455.
2016
Achimastos, A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., et al. (2016).  Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.. Hormones (Athens). 15(1), 8-14.
2011
Athyros, V. G., Giouleme O., Ganotakis E. S., Elisaf M., Tziomalos K., Vassiliadis T., et al. (2011).  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.. Arch Med Sci. 7(5), 796-805.
2010
Chimonas, T., Karagiannis A., Athyros V. G., Achimastos A., Elisaf M., & Panagiotakos D. B. (2010).  Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis.. Metab Syndr Relat Disord. 8(6), 523-9.
Chimonas, T., Athyros V. G., Ganotakis E., Nicolaou V., Panagiotakos D. B., Mikhailidis D. P., et al. (2010).  Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome.. Angiology. 61(1), 49-57.
Katsiki, N., Tziomalos K., Chatzizisis Y., Elisaf M., & Hatzitolios A. I. (2010).  Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?. Atherosclerosis. 211(1), 9-14.
2007
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., Kakafika A. I., Tziomalos K., Liberopoulos E. N., et al. (2007).  The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets. 11(2), 191-205.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
2006
Karagiannis, A., Athyros V. G., Papageorgiou A., Tziomalos K., & Elisaf M. (2006).  Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol. 47(5), 298-307.
2005
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές